Roche Influenza Treatment Approved by European Commission
By Cecilia Butini
Roche Holding AG said Monday that the European Commission has
approved its influenza treatment Xofluza.
Xofluza is a single-dose, oral treatment for uncomplicated
influenza in patients aged 12 and older which reduces viral
replication and can help patients recover more quickly, Roche
The company said Xoflusa was also approved as a post-exposure
prophylaxis, meaning as a preventative treatment for individuals
who have come in contact with someone infected with an influenza
The Commission's approval--which comes in the wake of a November
positive opinion from the Committee for Medicinal Products for
Human Use--is based on the results of phase 3 Capstone-1,
Capstone-2 and Blockstone studies, Roche said.
Write to Cecilia Butini at firstname.lastname@example.org
(END) Dow Jones Newswires
January 11, 2021 01:28 ET (06:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.